Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
HCW Presentation September 13, 2021
Canaccord Presentation August 12, 2021
Wedbush Presentation August 11, 2021
HCW Presentation March 9, 2021
SVB Leerink Presentation Feb 24, 2021
JPM Presentation Jan 14, 2021
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Press Releases
ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour – Positive Safety, Rapid Absorption and Absence of Interaction with Betamethasone is Basis for Phase 2 Study –
press release
February 26, 2015
Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…
Read moreObsEva Announces the Initiation of a Pivotal Phase 2 Study to Evaluate OBE001 for Improving Embryo Implantation and Clinical Pregnancy Rate in Women Undergoing IVF/ICSI
press release
November 18, 2014
Geneva, Switzerland, 18 November 2014 – ObsEva, a Swiss biopharmaceutical company dedicated to the development and commercialization of innovative drugs…
Read moreObsEva SA appoints Ben T.G. Tan as VP Commercial & Business Development
press release
September 10, 2014
Geneva, Switzerland, 10 September 2014 – ObsEva, a Swiss-based, specialty biopharmaceutical company dedicated to the development and commercialisation of innovative…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2019
May 8, 2019
ObsEva Annual General Meeting 2018
May 9, 2018
Upcoming Events
Stock Information
Latest Press Release
ObsEva Files half Year 2023 Financial Statements
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 –…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
